Literature DB >> 2537114

Phenotypic analysis of human myeloma cell lines.

C Duperray1, B Klein, B G Durie, X Zhang, M Jourdan, P Poncelet, F Favier, C Vincent, J Brochier, G Lenoir.   

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation, primarily in bone marrow, of a clone of plasma cells. The nature of the stem cells feeding the tumoral compartment is still unknown. To investigate this special point, we have studied the phenotypes of nine well-known human myeloma cell lines (HMCLs) and compared them with those of normal lymphoblastoid cell lines (LCLs). Twenty-four clusters of differentiation involved in B lymphopoiesis were investigated using a panel of 65 monoclonal antibodies (MoAbs). For each cluster, the percentage of positive cells and the antigen density were determined, giving rise to a "quantitative phenotype". We thus classified the HMCLs into two different groups: those with cytoplasmic mu chains (c mu+) and those without (c mu-). In the first (c mu+) group, comprising seven cell lines, the HMCLs had a phenotype of pre-B/B cells close to that of Burkitt's lymphoma cell lines. They expressed low densities of surface mu chains, without detectable cytoplasmic or surface light chains. Three of them were infected with the Epstein Barr virus (EBV). These c mu+ HMCLs bore most of the B-cell antigens except CD23. They expressed the CALLA antigen (CD10) and lacked the plasma-cell antigen PCA1. In contrast, LCLs expressed surface light chains, high densities of CD23, low densities of PCA1 antigen, and no CD10 antigen. The c mu- HMCLs had a plasma-cell phenotype, lacking most of the B-cell antigens and expressing high densities of PCA1 antigen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537114

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

2.  Spontaneous expression of a low affinity Fc receptor for IgA (Fc alpha R) on human B cell lines.

Authors:  I Millet; F Briere; C Vincent; F Rousset; C Andreoni; J E De Vries; J P Revillard
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6.

Authors:  Shangqin Liu; Ken-ichiro Otsuyama; Zi Ma; Saeid Abroun; Karim Shamsasenjan; Jakia Amin; Hideki Asaoku; Michio M Kawano
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 5.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

6.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

7.  Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Authors:  Jérémie Gaudichon; Francesco Milano; Julie Cahu; Lætitia DaCosta; Anton C Martens; Jack-Michel Renoir; Brigitte Sola
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

8.  CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Authors:  Elina Alaterre; Sebastien Raimbault; Hartmut Goldschmidt; Salahedine Bouhya; Guilhem Requirand; Nicolas Robert; Stéphanie Boireau; Anja Seckinger; Dirk Hose; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2017-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.